Stock Analysis

Alkem Laboratories Ltd - Fundamental Analysis

By Rajendra   20 Nov, 2022

Listed on BSE

Image Credit-Unsplash

52 week High/low - 3784/2835

CMP  - 3,125

Target - 3,680

Producing branded generics, generic medications, active pharmaceutical ingredients (APIs), and nutraceuticals, Alkem Laboratories Ltd sells them in India and other countries.

Image Credit-Unsplash

In terms of domestic sales, Alkem is the fifth-largest pharmaceutical firm in India.

Image Credit-Unsplash

During September 2022 quarter, the Company has filed 3 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals.

Image Credit-Unsplash

Company will be focusing on the molecules which have a large prescriber base, particularly antihypertensives and lipid management

Image Credit-Unsplash

company has strong balance sheet and is focusing on improving margins with cost optimization going forward.

Image Credit-Unsplash

New launches in the domestic market and focus on molecules, which have a large prescriber base indicate future growth visibility.

Image Credit-Unsplash

In 6-8 months, it is anticipated that the stock would reach its price goal of Rs. 3680.

Target

Image Credit-Unsplash